Clinical Trial Update: Erlotinib in Higher Risk Myelodysplastic Syndrome [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 clinical trial of erlotinib in higher-risk myelodysplastic syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: COMPLETED